KM 001 - Orvida Pharma
Alternative Names: KM-001 - Orvida PharmaLatest Information Update: 23 Apr 2026
At a glance
- Originator Kamari Pharma
- Developer Orvida Pharma
- Class Anti-inflammatories; Antipruritics; Calcium regulators; Keratolytics; Skin disorder therapies; Small molecules
- Mechanism of Action TRPV3 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pachyonychia congenita; Palmoplantar keratoderma
- Preclinical Ichthyosis
- No development reported Pruritus
Most Recent Events
- 15 Apr 2026 Kamari Pharma is now called Orvida Pharma
- 08 Oct 2025 phase-I development in Pachyonychia-congenita and Palmoplantar keratoderma in United Kingdom (NCT05956314)
- 28 Sep 2025 No recent reports of development identified for phase-I development in Pachyonychia-congenita(In the elderly, In adults) in United Kingdom (Topical, Cream)